Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
Mark Boguniewicz(University of Colorado Denver), Marius Ardeleanu(Regeneron (United States)), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Peter Lio(Northwestern University), Margitta Worm(Charité - Universitätsmedizin Berlin), Thomas Hultsch(Sanofi (United States)), Laurent Eckert(Sanofi (France)), Leda Mannent(Sanofi (France)), Neil M.H. Graham(UK Dementia Research Institute), Andrew Blauvelt(Veterans Health Administration), Lisa A. Beck(University of Rochester Medicine), Weily Soong(Allergy, Asthma and Clinical Research Center), Diamant Thaçi(University of Lübeck), Zhen Chen(The First People's Hospital of Shunde), Yufang Lü(Regeneron (United States)), Gianluca Pirozzi(Sanofi (United States)), Lawrence Sher(Peninsula Research), Jingdong Chao(AbbVie (United States)), Abhijit Gadkari(Regeneron (United States)), Ana B. Rossi(Sanofi (United States)), Marcella Ruddy(Regeneron (United States)), Jonathan Corren(California Allergy and Asthma Medical Group)
The Journal of Allergy and Clinical Immunology In Practice
January 14, 2021
Cited by 56
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k